drugset / Trial / NCT02207504
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Phase 1
Completed
24 enrolled
Dana-Farber Cancer Institute
Astellas Pharma Inc · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is comparing the combination of drugs Crizotinib and Enzalutamide as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2014-08
- Primary completion
- 2018-02-02
- Completion
- 2022-01-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crizotinib | Small molecule | — | Oral |
| Subject | Enzalutamide | Other / unclassified | — | Oral |